+1-518-621-2074 | US-Canada Toll Free Contact Us

Introduction of Improved Therapeutics Propels Global Colorectal Cancer

about us

Published on : Mar 07, 2017

ALBANY, NY, March 07, 2017: The publication, titled “Colorectal Cancer - Heat Map and Analysis,” provides a comprehensive data analysis of the global market and offers valuable business insights. The research report has been compiled using effective research methodologies. Analysts have studied the historical milestones of the global colorectal cancer and compared it to the present-day situation to map the trajectory of the overall market. The research report discusses the growing incidence of colorectal cancer and the variations in this chronic disease that require various therapeutics.

As of 2012, the colorectal cancer was the third common cause of deaths around the world according to the World Cancer Research Fund International. The organization states that about 54% of the colorectal cancer cases are registered in developed countries and this percentage is slated to rise in the coming years. Thus, the high prevalence of colorectal cancer has triggered a wave of efficient diagnostics, treatment, and therapeutics. The growing awareness amongst people about new screening tests and better treatments has also boosted the development of the global market. Furthermore, the increasing pool of geriatrics, initiatives taken by governments, and growing unmet medical needs in developing countries have also been instrumental in determining the progress of the global market.

Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=984797

Geographically, North America is expected to lead the global market in the coming years. The high prevalence of colorectal cancer, awareness about benefits of timely detection, and increasing investments in research and development of new drugs and therapeutics are expected to benefit the overall market in the near future. Additionally, the favorable reimbursement policies, establishment of excellent healthcare infrastructure, and strong presence of leading drug companies are assessed to be key factors propelling the growth of the global market.

Despite the steady market drivers, the global market faces a few challenges. Currently, the key hurdle for the global is the lack of awareness about the disease itself. The problem is further being complicated by the unaffordable healthcare in developing countries and poor reimbursement schemes. However, increasing expenditure on healthcare across the globe is expected to offer several lucrative opportunities to the global market in the foreseeable future.

Some of the key players operating in the global colorectal cancer market are Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Boehringer Ingelheim, Bayer HealthCare Pharmaceuticals, Taiho Pharmaceutical, and Pfizer, Inc. The research report profiles these players and provides a thorough analysis of their financial outlook, research and development activities, business and marketing strategies, and expansion plans for the forecast period. The publication also includes a Porter’s five forces analysis that determines the bargaining power of suppliers and buyers and the intensity of the competitive rivalry.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]